Small Centers with Big Ventures: Autologous Stem Cell Transplantation Survival Data

Asian Pac J Cancer Prev. 2019 Apr 29;20(4):987-990. doi: 10.31557/APJCP.2019.20.4.987.

Abstract

We present the first-ever autologous stem cell transplantation (ASCT) outcome data from a secondary-care healthcare facility. Albeit exact details of patient and disease characteristics and co-morbidity scores for all patients are not available, the engraftment and survival data is very similar to those published from large tertiary-care cancer centres, both regionally and internationally. Transplant Related Mortality (TRM) of 3.1% is within the expected range and includes a patient who died of acute drug reaction (ADR) during conditioning chemotherapy, prior to the ASCT. Furthermore, cyclophosphamide mobilization chemotherapy is given in the outpatient setting. This study is important in terms of healthcare resource optimization as well as patients’ convenience and highlights that ASCT can be performed in a safe and effective manner with comparable survival rates even at a DGH, provided the centre stays abreast with the recent developments and can offer its patients with standard of care treatment of the era.

Keywords: Outcome analysis; autologous stem cell transplantation; district general hospital; secondary care center.

MeSH terms

  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation / mortality*
  • Hospitals, Low-Volume / statistics & numerical data*
  • Humans
  • Lymphoma / classification
  • Lymphoma / mortality*
  • Lymphoma / pathology
  • Lymphoma / therapy
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Transplantation, Autologous